Cibinqo
FDA Approved
Contents
Description
Abrocitinib is a JAK1 inhibitor for the treatment of atopic dermatitis. It works by blocking the activity of Janus kinase 1 (JAK1), an enzyme involved in inflammation.
Indications & Therapeutic Use
Atopic dermatitis associated with hyper-IgE syndrome
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Cibinqo — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Cibinqo products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Cibinqo
| Generic Name | Cibinqo |
| Brands | 1 brand available |
| Active Ingredient | Abrocitinib |
| Drug Class | Atopic dermatitis associated with hyper-IgE syndrome |
| Manufacturer | Pfizer |
| Dosage Forms | Tablet |
| Medical Code | L04AA48 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes